Basic Xifaxan Information

• INN (International Nonproprietary Name): Rifaximin
• Brand Names Available In United States: Xifaxan (tablets 200 mg and 550 mg)
• ATC Code: A07AA11
• Forms & Dosages: Oral tablets 200 mg and 550 mg; oral suspension 100 mg/5 mL available in select markets (not widely in US)
• Manufacturers In United States: Salix Pharmaceuticals (a Bausch Health company)
• Registration Status In United States: FDA-approved for travelers’ diarrhea, IBS‑D, and hepatic encephalopathy
• OTC / Rx Classification: Prescription-only (Rx) in the United States

Everyday Use & Best Practices

Worried about when to take Xifaxan and how it fits into a busy day?

Morning Vs Evening Dosing

Follow the prescription exactly; dosing for xifaxan (rifaximin) depends on the indication and tablet strength.

For IBS‑D in adults the usual regimen is Xifaxan 550 mg three times daily for 14 days.

For travelers’ diarrhea due to non‑invasive E. coli the regimen is 200 mg three times daily for 3 days.

For hepatic encephalopathy chronic prevention, typical dosing is 550 mg twice daily.

Choose evenly spaced times to keep gut levels steady — for TID try breakfast, mid‑afternoon, and dinner.

If a dose is missed take it when remembered unless it’s close to the next dose; do not double doses.

Taking With Or Without Meals

Xifaxan tablets may be taken with or without food in most cases.

If nausea occurs consider a light meal with dosing to improve tolerability.

Store tablets at 20–25°C (68–77°F) and protect from moisture.

• Checklist: set reminders, keep a pillbox, track doses in a simple chart.
• Warning: Xifaxan is prescription-only; do not use for fever or bloody diarrhea without medical evaluation.

Safety Priorities

Are there people who should avoid Xifaxan or extra precautions to take?

Who Should Avoid It

Do not use Xifaxan if there is a known hypersensitivity to rifaximin or related rifamycins such as rifampicin, rifabutin, or rifapentine.

Xifaxan is not indicated for bacterial diarrhea with fever or bloody stools and may worsen outcomes in those scenarios.

Exercise caution in severe hepatic impairment (Child‑Pugh C) because data are limited and monitoring is advised.

Patients with a history of Clostridioides difficile infection require caution, since all antibiotics can increase C. difficile risk.

Pediatric use has been studied and is generally for those aged 12 years and older for some indications; safety in younger children is not established.

Activities To Limit

No major activity restrictions are required given minimal systemic absorption and low sedation risk.

If dizziness or fatigue occurs as an adverse effect avoid driving or operating heavy machinery until effects resolve.

For hepatic encephalopathy patients continue baseline measures such as lactulose and monitor mental status closely; do not stop other HE therapies without clinician advice.

• Contraindications: rifamycin allergy, febrile or bloody diarrhea.
• When To Contact Clinician: fever, bloody stool, severe rash, severe diarrhea, or worsening confusion.

Dosage & Adjustments

Not sure which Xifaxan dose applies to you or how to adjust for age, kidneys, or liver?

General Regimen

Standard adult regimens from labeling are clear for each indication.

For travelers’ diarrhea caused by non‑invasive E. coli use rifaximin 200 mg orally three times daily for 3 days.

For IBS‑D in adults the recommended regimen is Xifaxan 550 mg orally three times daily for 14 days.

For reduction in recurrence of hepatic encephalopathy the usual regimen is 550 mg orally twice daily as chronic therapy.

Available tablet strengths in the US are 200 mg and 550 mg; an oral suspension (100 mg/5 mL) exists in select markets but is not widely available in the US.

Special Cases

Pediatrics: dosing has been studied and approved for some indications in patients 12 years and older; younger children lack established safety data.

Elderly patients usually need no routine dose change but monitor hepatic function.

Renal impairment does not require dosage adjustment due to minimal systemic absorption.

Severe liver impairment requires cautious use and monitoring for efficacy and adverse effects.

• Missed dose: take when remembered unless close to the next dose; do not double.
• Overdose: supportive care; no specific antidote because of low systemic absorption.

User Testimonials

What do real patients say about symptom relief, side effects, and access?

Positive Reports

Many adults with IBS‑D report reduced stool frequency and urgency following a 14‑day course of Xifaxan 550 mg TID, with symptom relief lasting several weeks for some.

Patients with hepatic encephalopathy on chronic 550 mg BID commonly report fewer encephalopathy recurrences when rifaximin is used along with lactulose.

Travelers’ diarrhea users often note rapid symptom control after a 3‑day course of 200 mg TID.

Common Challenges

Typical complaints include GI side effects such as nausea, constipation, abdominal pain, bloating, and occasional dizziness or headache.

Some IBS‑D patients experience symptom recurrence and discuss retreatment with their clinician.

Cost and insurance coverage can be a barrier because Xifaxan is prescription-only and branded in the US.

• "After the 14‑day course my urgency improved and I felt confident leaving home again." — anonymized patient report.
• "Rifaximin plus lactulose kept my hospital visits down." — anonymized patient report.
• "Insurance made it hard to get a refill when symptoms came back." — anonymized patient report.

• Checklist For Clinician Visits: bring a symptom diary, list of current medications, and notes on prior antibiotic responses.

Buying Guide

How and where can patients get Xifaxan, and what are common cost-saving options?

Pharmacy Sources

Xifaxan (brand by Salix Pharmaceuticals) is prescription-only in the United States and can be filled at community or chain pharmacies or via mail-order specialty pharmacies.

For hepatic encephalopathy or chronic use, specialty pharmacies often manage prior authorization and ongoing supplies.

Other countries may market rifaximin under names like Normix, Flonorm, or Rifaxen and may offer oral suspensions, but the US market primarily sells tablets.

Price Comparison

Cost varies by dose, quantity, insurance plan, and pharmacy chosen.

Generics are available in some regions but availability varies; lower-cost options are more common outside the US.

If cost is an issue ask your clinician about manufacturer assistance programs, coupons, or insurance prior authorization strategies.

• Bring to Pharmacy: valid prescription, insurance card, and any prior authorization paperwork.

In our online pharmacy, xifaxan is available without a prescription with discreet delivery to United States in 5-14 days.

What’s Inside & How It Works

Curious what the tablets contain and why they act mainly inside the gut?

Ingredients Overview

The active ingredient is rifaximin, a rifamycin derivative with minimal systemic absorption when taken orally.

Tablet strengths commonly available in the US are 200 mg and 550 mg.

An oral suspension formulation (100 mg/5 mL) is available in select international markets but not widely in the United States.

Inactive ingredients vary by manufacturer; consult packaging if you have severe excipient allergies.

Mechanism Basics

Rifaximin works locally in the intestinal lumen by binding the beta subunit of bacterial DNA‑dependent RNA polymerase and inhibiting bacterial RNA synthesis.

Its local antibacterial activity reduces pathogenic or overgrown gut bacteria without significant systemic exposure, which lowers systemic side effects and drug interactions.

Because of this local action rifaximin is classified under ATC A07AA11 as an intestinal antiinfective and is useful for gut-limited conditions such as IBS‑D, travelers’ diarrhea, and hepatic encephalopathy.

Main Indications

Which conditions is Xifaxan approved to treat, and what about off‑label uses?

Approved Uses

FDA‑approved indications in the United States include travelers’ diarrhea caused by non‑invasive E. coli at 200 mg TID for 3 days.

FDA approval also covers IBS‑D in adults with Xifaxan 550 mg TID for 14 days.

For reduction in recurrence of hepatic encephalopathy rifaximin 550 mg twice daily is an approved chronic prevention regimen.

Off‑Label Uses

Clinicians sometimes prescribe rifaximin off‑label for small intestinal bacterial overgrowth (SIBO) and other dysbiosis-related GI symptoms, though evidence is variable.

Repeat courses may be required for recurrent symptoms; this is a clinician decision weighing risks and benefits.

• Do not use Xifaxan when systemic infection, fever, or bloody diarrhea is suspected.

Interaction Warnings

Will Xifaxan interact with food or other medicines I take every day?

Food Interactions

Food has minimal impact on rifaximin effectiveness, and tablets can be taken with or without meals.

If nausea occurs taking doses with food may improve tolerability.

Maintain hydration during diarrheal illness; no routine dietary restrictions are required with Xifaxan.

Drug Conflicts

Because rifaximin is minimally absorbed there is a low risk of systemic drug–drug interactions.

Avoid use in patients with known rifamycin allergy due to hypersensitivity risk.

Monitor clinical status when combining with other hepatically metabolized drugs in patients with severe hepatic impairment.

Concurrent use of multiple antibiotics raises the risk of C. difficile infection, so be vigilant for worsening diarrhea after treatment.

• Watch For: new or worsening diarrhea, fever, or abdominal pain after treatment.

Latest Evidence & Insights

What do recent trials and reviews say about rifaximin effectiveness for its indications?

• Rifaximin 550 mg TID for 14 days demonstrates modest but clinically meaningful reductions in stool frequency and urgency for many IBS‑D patients, with symptom benefit lasting weeks for some.
• For hepatic encephalopathy trials support rifaximin 550 mg BID combined with lactulose to reduce recurrence of encephalopathy events.
• Short rifaximin courses (200 mg TID for 3 days) shorten duration of travelers’ diarrhea caused by non‑invasive E. coli.
• Emerging research explores rifaximin for SIBO and microbiome modulation, but results are heterogeneous and retreatment strategies vary.

Practical takeaway: Xifaxan is most useful when a local gut antibacterial effect aligns with the clinical goal, not for systemic infections.

Alternative Choices

What other medicines might be considered depending on the problem being treated?

Alternatives vary by indication and by whether the goal is symptomatic control or antibacterial effect.

For IBS‑D symptomatic control consider loperamide or eluxadoline; these are not antibacterial but help reduce stool frequency and urgency.

For hepatic encephalopathy lactulose remains the mainstay, and neomycin has been used as an older non‑absorbed alternative off‑label.

For travelers’ diarrhea systemic options such as ciprofloxacin or metronidazole may be used based on the likely pathogen and resistance patterns but carry greater systemic side‑effect risk.

Non‑antibiotic strategies such as low‑FODMAP dietary adjustments, soluble fiber, and selected probiotics may help recurrent IBS symptoms and should be discussed with a clinician.

Regulation Snapshot

Is rifaximin approved and how is it regulated across regions?

• Rifaximin (INN) is marketed under Xifaxan in the United States, Canada, and many EU countries.
• Other brand names include Normix (Italy) and regional variants such as Flonorm or Rifaxen in parts of Latin America.
• ATC classification is A07AA11 (intestinal antiinfectives).
• The FDA has approved rifaximin for travelers’ diarrhea, IBS‑D, and hepatic encephalopathy in the United States.
• Legal classification is prescription-only (Rx) across major markets including the US, EU, and Canada.

• Storage/Transport: store tablets at 20–25°C (68–77°F) and protect from moisture; permitted excursions 15–30°C (59–86°F).

FAQ

Have quick questions about Xifaxan? Here are succinct answers patients often ask.

1. Can I take Xifaxan for any diarrhea? No; Xifaxan is approved for traveler’s diarrhea caused by non‑invasive E. coli and should not be used for bloody or febrile diarrhea without medical evaluation.
2. Is it safe long‑term? For hepatic encephalopathy chronic rifaximin 550 mg BID is used under medical supervision; for IBS‑D short courses are typical and repeat courses may be directed by a clinician.
3. What are common side effects? Common effects include nausea, constipation, abdominal pain, flatulence, and headache; rare issues include rash and hypersensitivity.
4. Can pregnant or breastfeeding patients take it? Discuss with a clinician; use only if benefits outweigh risks and under medical supervision.
5. Can I get it over the counter? No; rifaximin is prescription-only in major markets including the United States.

• When To Call Your Provider: fever, bloody stool, severe rash, worsening encephalopathy, or severe persistent diarrhea.

Guidelines For Proper Use

What practical steps help patients use Xifaxan safely and effectively at home?

Confirm the indication with your clinician and ensure that symptom patterns match the labelled uses for travelers’ diarrhea, IBS‑D, or hepatic encephalopathy.

Follow the prescribed dosing exactly: 200 mg TID × 3 days for travelers’ diarrhea; 550 mg TID × 14 days for IBS‑D; 550 mg BID chronically for HE prevention when indicated.

Space doses evenly through the waking day; if nausea occurs take with food.

Do not use Xifaxan for bloody or febrile diarrhea without immediate medical evaluation.

Store tablets at 20–25°C (68–77°F) and protect from moisture.

Report severe side effects such as rash, severe diarrhea, jaundice, or worsening encephalopathy to your clinician promptly.

• At‑Home Monitoring Checklist: record stool frequency, urgency, abdominal pain scores, any new rashes, and mental status changes for HE patients.
• Clinician Guidance: document prior C. difficile history, check liver status in severe hepatic impairment, and consider cost/coverage issues when planning treatment.

Delivery Across United States